Cerbios-Pharma has been acquired by HAS Healthcare
May 2025 — Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Cerbios is a Swiss company specializing in the development and manufacturing of both chemical and biological active pharmaceutical ingredients (APIs). In addition to advancing its own product pipeline, Cerbios offers third-party CDMO services for high potency active pharmaceutical ingredients (HPAPIs), recombinant proteins and antibody-drug conjugates (ADCs), supporting projects from preclinical development through to clinical and commercial supply.
HAS is a leading Swiss CDMO, specializing in high-potency substances. The company offers a full range of customized services, including laboratory development, manufacturing, regulatory support and approval. HAS develops and manufactures APIs, current good manufacturing practice (cGMP) advanced intermediates, HPAPIs and anticancer compounds exclusively for its clients, supporting projects from clinical development through to commercial supply.
Our role in the transaction
Oaklins’ team in Switzerland acted as the exclusive sell-side advisor to the shareholders and management of Cerbios, facilitating a successful transaction with the preferred partner.
Rudolf Dudler
Member of the board and co-owner, Cerbios-Pharma S.A.
Talk to the deal team
Daniel Eichenberger
Oaklins Switzerland
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreSynergia and Bolster have secured acquisition financing for Life & Mobility
Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.
Learn more